OmniComm Systems Inc

OmniComm Systems — 10th Annual AeA Micro Cap Financial Conference (May 2008)

31 slides from OmniComm Systems's conference presentation, May 6, 2008

  1. Slide 1: SYSTEMS

    Slide 1: SYSTEMS

    SYSTEMS OMNIC@M AGEMEN

  2. Slide 2: 10th Annual AeA Micro Cap Financial Conference

    Slide 2: 10th Annual AeA Micro Cap Financial Conference

    10 th Annual AeA Micro Cap Financial Conference May 6, 2008 (OMCM) Exhibit 99.1

  3. Slide 3: Notice Regarding Forward Looking Statements

    Slide 3: Notice Regarding Forward Looking Statements

    NOTICE REGARDING FORWARD LOOKING STATEMENTS Page Statements contained in this presentation, which are not historical facts, such as statements about prospective earnings, savings, revenues, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to

  4. Slide 4: Company Profile

    Slide 4: Company Profile

    Company Profile Page OmniComm Systems is an eClinical software and services company dedicated to helping the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments through the use of innovative and cutting ed

  5. Slide 5: Traditional Paper-Based Clinical Trial Data Collection Cycle

    Slide 5: Traditional Paper-Based Clinical Trial Data Collection Cycle

    Traditional Paper-Based Clinical Trial Sponsor Company Clinical Database Data Collection Cycle Page -1- - Clinical Study is defined - Paper CRFs are printed - 3 - - Patients enter study - Doctor fills patient chart (source doc) - 4 - - Data is transcribed from source doc to patient CRFs - 6 - - Data

  6. Slide 6: Improved Process Using Electronic Data Capture

    Slide 6: Improved Process Using Electronic Data Capture

    Improved Process Using Electronic Data Capture Page OMCM’s TrialMaster Central Clinical DB Data Entry Sites Enter and Validate over the Web Define Study Validate Centrally Resolve discrepancies over the Web

  7. Slide 7: EDC Adoption and Growth

    Slide 7: EDC Adoption and Growth

    EDC Adoption and Growth Page Source: 2007 Health Industry Insights Report Spending on EDC solutions is expected to increase at a 14.7% CAGR and total more than $3.1B for 2006 -2011. 60% of all new clinical trials (Phases I- III) are expected to use EDC in 2008.

  8. Slide 8: eClinical Market Adoption Rate (U.S. only)

    Slide 8: eClinical Market Adoption Rate (U.S. only)

    eClinical Market Adoption Rate (U.S. only) Page $1.8B $1.5B $1.2B $900M $600MM $500MM eClinical Total Market (3) 9,000 7,500 6,000 4,500 3,000 2,500 # of Trials Using EDC (2) 90% 75% 60% 45% 30% 25% eClinical Adoption Rate (1) 2010 2009 2008 2007 2006 2005 (1) Health Industry Insights, 2007 (2) Clin

  9. Slide 9: OmniComm Corporate Overview

    Slide 9: OmniComm Corporate Overview

    OMNICOMM CORPORATE OVERVIEW Page (OTCBB: OMCM) • Company commenced EDC operations in February 1999 • 85 employees today • Headquartered in Ft. Lauderdale with offices in Germany and Russia • TrialMaster ™ is OMCM’s proprietary EDC platform • Version 4.0 released early 2007 • OC Connect (Oracle Bridg

  10. Slide 10: EDC Drives Clinical Trial Improvements

    Slide 10: EDC Drives Clinical Trial Improvements

    EDC Drives Clinical Trial Improvements Page Clinical Trials – crucial to success in R&D for Life Sciences organizations EDC is a classic disruptive technology and the market is poised for explosive growth Health Industry Insights predicts that at the end of 2007 approximately 45% of all new clinical

  11. Slide 11: Full Coverage Across Entire eClinical Spectrum

    Slide 11: Full Coverage Across Entire eClinical Spectrum

    Full Coverage Across Entire eClinical Spectrum EDC ePRO Imaging Safety, Handling IVR eProtocol Design Coding

  12. Slide 12

    Slide 12

  13. Slide 13: Competitive Advantages

    Slide 13: Competitive Advantages

    Competitive Advantages Flexible Connectivity Clinical Experience Unparalleled Customer Service Accelerating Momentum Robust Features Cost Competitive Position • Flexible EDC Solution offers multiple platform support (Oracle, SQL) • In addition to our experienced management team, our employees bring

  14. Slide 14: Scalable Business Model

    Slide 14: Scalable Business Model

    Scalable Business Model Application Service Provider (“ASP”) Technology Transfer Technology Transition • OMCM Offers EDC under a “ Crawl, Walk, Run ” Basis • Three Business Models Provides Opportunity to Service Broader Sc ope of the Clinical Trial Industry Applicable for larger customers that will

  15. Slide 15: OmniComm's Milestones

    Slide 15: OmniComm's Milestones

    OmniComm’s Milestones 2000 – TrialMaster Version 2.0 released 2004 – Phase I specific TrialMaster product developed for improved productivity, responsiveness, data accuracy and reduced trial time 2006 – OmniComm opens European Office and begins ramping up 1H’08 – Over $3 MM in contracts are booked i

  16. Slide 16: Strategic Focus

    Slide 16: Strategic Focus

    Strategic Focus • OmniComm’s strategy has been to focus on the underserved small to medium trial sponsor market • New capabilities and technology has now allowed us to support the larger pharma & CRO market as well – Global Operations/Support – Integration with Oracle Clinical • CRO Partnership Prog

  17. Slide 17: Recent Highlights

    Slide 17: Recent Highlights

    Recent Highlights Medical Device 388K 185K Average Deal Size in $ 3.1 Q1 Fiscal 2008 10.2 Fiscal 2007 Academic & Other CRO Bio- Tech Pharma # of New Trials Contract $ in MM’s We entered into 18 CRO Partnership Agreements in Fiscal 2007 and 4 Agreements Year-to-Date in Fiscal 2008

  18. Slide 18: Recent Highlights

    Slide 18: Recent Highlights

    Recent Highlights Major Highlights Valeant Pharmaceuticals Chooses OmniComm over 6 Competing EDC Companies due to clear distinction in services and support Major West Coast Biopharmaceutical Company 5 year, 1.5 million Enterprise Finalist in the National Cancer Institute’s (NCI) EDC Evaluation OMCM

  19. Slide 19: Experienced Management Team

    Slide 19: Experienced Management Team

    Experienced Management Team – 110 Years All OMCM Ronald Linares CFO Organon, Duphar (Solvay), DMV Cornelis Wit, President & CEO Industry Related Experience 110 Years of Experience All OMCM Randall Smith Chairman & CTO Oracle, PHT Corp, Clinical Data Solutions, Pfizer Stephen Johnson COO Eli Lilly, J

  20. Slide 20: SYSTEMS

    Slide 20: SYSTEMS

    SYSTEMS OMNIC@M AGEMEN

  21. Slide 21: Financial Overview

    Slide 21: Financial Overview

    Financial Overview Ron Linares, Chief Financial Officer

  22. Slide 22: Long-term Growth Strategy

    Slide 22: Long-term Growth Strategy

    Long-term Growth Strategy Engage smaller Phase I contracts; secure Follow-on Unveil TrialMaster v4 Leverage for larger Phase II, III contracts Emphasize Clinical expertise and ease of integration with industry partners Int’l Expansion; Acquisition Secure Short-term Clients Penetrate Fortune 100 Spon

  23. Slide 23: Financial Highlights, FY'07

    Slide 23: Financial Highlights, FY'07

    Financial Highlights, FY’07 5000 10000 15000 20000 25000 30000 35000 40000 45000 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Mar-08 Total Pipeline Probability Adjusted Sales Pipeline 2006 – Q1 2008 In MM’s

  24. Slide 24: Summarized Operations

    Slide 24: Summarized Operations

    Summarized Operations % of % of 2007 Revenues 2006 Revenues Total revenues 3,723,841 $ 2,763,039 $ Cost of sales 1,033,824 27.8% 969,323 35.1% Gross margin 2,690,017 72.2% 1,793,716 64.9% Salaries, benefits and related taxes 5,886,663 158.1% 3,986,311 144.3% Total Operating Expenses 7,906,033 212.3%

  25. Slide 25: Revenue Segmentation – by Client Type

    Slide 25: Revenue Segmentation – by Client Type

    Revenue Segmentation – by Client Type 18% 31% 22% 18% 11% Pharmaceutical Bio-Tech Medical Device CRO Academic & Other

  26. Slide 26: Contract Growth

    Slide 26: Contract Growth

    Contract Growth $0 $750,000 $1,500,000 $2,250,000 $3,000,000 $3,750,000

  27. Slide 27: Average Trial Size – by Trial Phase

    Slide 27: Average Trial Size – by Trial Phase

    Average Trial Size – by Trial Phase N/A 159,707 N/A Phase IV 536,324 277,638 222,691 Phase III 530,172 133,917 156,939 Phase II 92,469 96,102 77,686 Phase I 2008 2007 2006 Realizing pricing power in Fiscal 2008 in Phase II and Phase III segment of the clinical trial market

  28. Slide 28: Capital Structure, Cash and Sustainability

    Slide 28: Capital Structure, Cash and Sustainability

    Capital Structure, Cash and Sustainability OTC Bulletin Board: OMCM Stock Price: $0.54 52 Week Range: $0.71 - $0.48 Market Cap: $40MM Fully Diluted Market Cap: $54MM Common Stock 74,701,008 Series A Preferred Stock 2,810,149 (1) Secured Convertible Debt 3,977,563 (2) Warrants & Options 17,925,890 (3

  29. Slide 29: Capital Relationships

    Slide 29: Capital Relationships

    Capital Relationships Closed Secured Convertible Debt round of financing on 2/29/08 • $2.25 MM Convertible at $0.595/share • 75% Warrant Coverage at $0.75/share Strong Existing Relationship with Noesis Capital • Boca Raton, FL based Placement Agent & Money Management Firm • Funding of Approximately

  30. Slide 30: Investment Highlights

    Slide 30: Investment Highlights

    Investment Highlights Industry Growth Customer Service Clinical expertise International Platform Experienced Management Sales Momentum • Company culture focused on providing the best Customer Service separates OmniComm from its peers and creates substantial value • Invaluable to the customization pr

  31. Slide 31: Thank You

    Slide 31: Thank You

    Thank You For more information, please contact: Stephen Johnson, Ronald Linares, Chief Operating Officer Chief Financial Officer sjohnson@omnicomm.com rtlcfo@omnicomm.com 954-473-1254

Source: SEC EDGAR · 8-K filed May 6, 2008